HIV/AIDS treatment and HIV vaccines for Africa (Q34726113)

4 August 2017

1 reference

title

HIV/AIDS treatment and HIV vaccines for Africa (English)

1 reference

4 August 2017

1 reference

4

John Nkengasong

1 reference

4 August 2017

Paul J Weidle

1

1 reference

4 August 2017

Timothy D Mastro

series ordinal

2

1 reference

4 August 2017

Alison D Grant

series ordinal

3

1 reference

4 August 2017

Doris Macharia

series ordinal

5

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 June 2002

1 reference

4 August 2017

1 reference

4 August 2017

359

1 reference

4 August 2017

9325

1 reference

4 August 2017

2261-2267

1 reference

AIDS meeting. Companies, donors pledge to close gap in AIDS treatment.

4 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909297-8

7 January 2021

Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909297-8

7 January 2021

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909297-8

7 January 2021

Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909297-8

7 January 2021

Indian company offers low cost AIDS drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909297-8

7 January 2021

Access to treatment for HIV in developing countries; statement from international seminar on access to treatment for HIV in developing countries, London, June 5 and 6, 1998

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909297-8

7 January 2021

Preventing antiretroviral anarchy in sub-Saharan Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909297-8

7 January 2021

PUBLIC HEALTH: HIV/AIDS Treatment for Millions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909297-8

7 January 2021

Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909297-8

7 January 2021

Community-based approaches to HIV treatment in resource-poor settings

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909297-8

7 January 2021

Resistance to antiretroviral therapy among patients in Uganda

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909297-8

7 January 2021

World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909297-8

7 January 2021

Drug susceptibility of subtypes A,B,C,D, and E human immunodeficiency virus type 1 primary isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909297-8

7 January 2021

Human immunodeficiency virus type 1 subtype F reverse transcriptase sequence and drug susceptibility.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909297-8

7 January 2021

Sequence and drug susceptibility of subtype C protease from human immunodeficiency virus type 1 seroconverters in Zimbabwe

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909297-8

7 January 2021

Genetic variation and susceptibilities to protease inhibitors among subtype B and F isolates in Brazil

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909297-8

7 January 2021

Sequence diversity of the reverse transcriptase of human immunodeficiency virus type 1 from untreated Brazilian individuals.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909297-8

7 January 2021

Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909297-8

7 January 2021

Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909297-8

7 January 2021

Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909297-8

7 January 2021

Adverse effects of antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909297-8

7 January 2021

Development and significance of resistance to protease inhibitors in HIV-1-infected adults under triple-drug therapy in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909297-8

7 January 2021

HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909297-8

7 January 2021

Impact of human immunodeficiency virus type 1 (hiv-1) subtype on women receiving single-dose nevirapine prophylaxis to prevent hiv-1 vertical transmission (hiv network for prevention trials 012 study).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909297-8

7 January 2021

Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909297-8

7 January 2021

Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909297-8

7 January 2021

Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909297-8

7 January 2021

Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909297-8

7 January 2021

Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d'Ivoire: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909297-8

7 January 2021

Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Cotrimo-CI Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909297-8

7 January 2021

Initiating co-trimoxazole prophylaxis in HIV-infected patients in Africa: an evaluation of the provisional WHO/UNAIDS recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909297-8

7 January 2021

Plasmodium falciparum cross-resistance between trimethoprim and pyrimethamine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909297-8

7 January 2021

23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909297-8

7 January 2021

Public Health Implications of Antiretroviral Therapy and HIV Drug Resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909297-8

7 January 2021

Adherence to protease inhibitor therapy and outcomes in patients with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909297-8

7 January 2021

Are advances in treatment changing views about high-risk sex?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909297-8

7 January 2021

New hope for an AIDS vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909297-8

7 January 2021

The search for an HIV vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909297-8

7 January 2021

Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909297-8

7 January 2021

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909297-8

7 January 2021

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909297-8

7 January 2021

Disappointing data scuttle plans for large-scale AIDS vaccine trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909297-8

7 January 2021

First trial of the HIV-1 vaccine in Africa: Ugandan experience

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909297-8

7 January 2021

Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909297-8

7 January 2021

Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909297-8

7 January 2021

A DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multi-specific T cell responses in rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909297-8

7 January 2021

The HIV vaccine pipeline, from preclinical to phase III.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909297-8

7 January 2021

10.1016/S0140-6736(02)09297-8

Identifiers

DOI

1 reference

release_trhxvfm43jfkdnl3tjvewq3ohi

4 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/trhxvfm43jfkdnl3tjvewq3ohi

24 November 2022

mapped directly with Wikidata item

1 reference